Tranexamic acid
Cyklokapron, Lysteda, Tranexamic Acid (tranexamic acid) is a small molecule pharmaceutical. Tranexamic acid was first approved as Cyklokapron on 1986-12-30. It is used to treat inherited blood coagulation disorders and subarachnoid hemorrhage in the USA. The pharmaceutical is active against plasminogen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cyklokapron, Lysteda, Tranexamic acid (discontinued: Cyklokapron, Tranexamic acid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tranexamic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LYSTEDA | Amring Pharmaceuticals | N-022430 RX | 2009-11-13 | 1 products, RLD, RS |
| TRANEXAMIC ACID | Exela Pharma Sciences | N-212020 RX | 2019-04-15 | 1 products, RLD, RS |
| CYKLOKAPRON | Pfizer | N-019281 RX | 1986-12-30 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cyklokapron | New Drug Application | 2025-01-30 |
| pure whitenol serum | unapproved drug other | 2015-03-06 |
| rosacea therapy | C200263 | 2023-12-29 |
| skinmd laboratories pure whitenol intensive | unapproved drug other | 2019-12-24 |
| skinmd laboratories pure whitenol serum | unapproved drug other | 2019-12-24 |
| skinmd laboratories revitox blue | unapproved drug other | 2018-11-28 |
| tranexamic acid | ANDA | 2025-03-01 |
| tranexamic acid in sodium chloride | ANDA | 2025-01-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| subarachnoid hemorrhage | EFO_0000713 | D013345 | I60 |
| inherited blood coagulation disorders | — | D025861 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRANEXAMIC ACID, TRANEXAMIC ACID, AMNEAL | |||
| 2024-04-16 | CGT | ||
HCPCS
No data
Clinical
Clinical Trials
870 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 2 | — | 2 |
| Colectomy | D003082 | — | — | — | — | — | 1 | — | 1 |
| Gastrectomy | D005743 | — | — | — | — | — | 1 | — | 1 |
| Pancreaticoduodenectomy | D016577 | — | — | — | — | — | 1 | — | 1 |
| Esophagectomy | D016629 | — | — | — | — | — | 1 | — | 1 |
| Biliary tract surgical procedures | D001662 | — | — | — | — | — | 1 | — | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 1 | — | 1 |
| Femoral fractures | D005264 | — | S72 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 1 | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | 1 | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | 1 | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 1 | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tranexamic acid |
| INN | tranexamic acid |
| Description | Tranexamic acid is a monocarboxylic acid. It has a role as an antifibrinolytic drug and a hematologic agent. It is functionally related to a cyclohexanecarboxylic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H]1CC[C@H](C(=O)O)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1197-18-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL877 |
| ChEBI ID | 48669 |
| PubChem CID | 5526 |
| DrugBank | DB00302 |
| UNII ID | 6T84R30KC1 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Tranexamic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,482 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,640 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use